Heron Therapeutics, Inc. filed a current report on November 9, 2026, disclosing an Asset Purchase Agreement signed on November 8, 2026, under which the company agreed to sell substantially all of its assets to CorMedix Inc. for $145.0 million in cash, 14,583,333 shares of CorMedix common stock, potential royalties, and earn-out payments.
Key Highlights
- Asset Sale Agreement: Heron Therapeutics and CorMedix Inc. entered into an Asset Purchase Agreement on November 8, 2026, covering substantially all of Heron's assets, excluding federal income tax net operating loss carryforwards and certain other tax attributes.
- Cash Consideration: CorMedix agreed to pay $145.0 million in cash, subject to adjustments for closing cash and net working capital, with $2.0 million deposited into escrow with Citibank, N.A. at closing.
- Stock Consideration: CorMedix agreed to issue 14,583,333 shares of its common stock, par value $0.001 per share, to Heron as part of the consideration.
- Royalties: CorMedix agreed to pay royalties equal to 5.0% of aggregate annual net sales of CINVANTI, SUSTOL, and products covered by the company's multi-product Development and License Agreement exceeding $25.0 million in each of calendar years 2027, 2028, and 2029, if and when payable.
- Earn-Out Payments: Potential earn-out payments of $25.0 million if ZYNRELEF net sales for calendar year 2028 reach $65.0 million, and an additional $30.0 million if such net sales reach $95.0 million, payable in cash, CorMedix common stock, or a combination.
- Termination Fee: The company may terminate the Purchase Agreement to pursue a superior proposal, subject to payment of a $4.0 million termination fee and other conditions.
- No Liquidation Planned: According to the filing, the company does not intend to liquidate following the closing and the board intends to evaluate strategic transactions and opportunities for use of the proceeds.
Heron Therapeutics Asset Sale to CorMedix: Transaction Terms and Board Obligations
According to the filing, Heron Therapeutics, Inc. (NASDAQ:HRTX) and CorMedix Inc. executed an Asset Purchase Agreement on November 8, 2026, under which Heron agreed to sell substantially all of its assets to CorMedix. Excluded from the sale are the company's federal income tax net operating loss carryforwards and certain other tax attributes. The filing states that CorMedix's obligation to consummate the asset sale is not subject to any financing conditions.
The filing discloses that Heron intends to use a portion of the net proceeds to repay all amounts outstanding under its Working Capital Facility Agreement dated August 9, 2023, with Hercules Capital, Inc. serving as administrative agent and collateral agent. Following the closing, Heron will retain the CorMedix shares issued to it, rights to future royalties, earn-out payments, its net operating loss carryforwards, and cash on hand. The company's board disclosed that it "intends to actively evaluate various strategic transactions and opportunities for the use of the proceeds of the Asset Sale, including acquiring or investing in additional businesses or assets, which may or may not be pharmaceutical or biotechnology businesses or assets."
The Purchase Agreement includes a non-solicitation covenant restricting Heron from seeking competing proposals, subject to certain exceptions. The filing notes that following the closing, Heron will be subject to a five-year covenant not to compete in chemotherapy-induced or post-operative nausea and vomiting treatments using injectable products containing aprepitant or granisetron, or post-operative pain treatments with non-opioid anesthetics containing bupivacaine or low-dose meloxicam. A three-year mutual non-solicitation of employees is also included. The representations and warranties of the parties do not survive the closing, and the company will have no liability following the closing for any breach of its representations and warranties, other than in the case of fraud, according to the filing.
What Was Disclosed
Heron Therapeutics disclosed entry into an Asset Purchase Agreement with CorMedix Inc. on November 8, 2026, providing for the sale of substantially all of Heron's assets for $145.0 million in cash, 14,583,333 CorMedix shares, royalties tied to specified product sales, and potential earn-out payments of up to $55.0 million linked to ZYNRELEF net sales targets.



Please wait processing your request...